• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

byConstance Wu
June 13, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

1. Angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) were not shown to affect the risk of coronavirus disease 2019 (Covid-19).

2. ACE inhibitors and ARBs were shown to be more frequently used among Covid-19 patients.

Evidence Rating Level: 3 (Average)

Study Rundown: Angiotensin-converting enzyme 2 (ACE2), a membrane bound aminopeptidase abundantly expressed in the lungs and heart, is used by coronaviruses for entrance into the cell. ACE inhibitors and ARBs increase ACE2 expression and block the renin-angiotensin-aldosterone system (RAAS). Therefore, there has been concern that using these drug therapies can alter infection susceptibility. As such, the study evaluated the association between RAAS blockers and the risk of Covid-19. The study collected patient data from resident in Lombardy, Italy capturing Covid-19 infection status, underlying cardiovascular disease, and cardiovascular medication use. No evidence was found to support the use of ACE inhibitors or ARBs to be independently associated with the risk of Covid-19. This retrospective study was limited by drug use data was assessed through prescriptions. As such, actual drug consumption could not be assessed. Another limitation was the doses studied were those available in Italy, which may not reflect the doses present in other countries. Nonetheless, this study was strengthened by conducting a case-control trial to understand the relationship between underlying RAAS blocker drug use and Covid-19 risk. For physicians, these findings highlight the importance of continuing patients on their RAAS blockers to maintain cardiovascular health as these medications likely do not alter Covid-19 risk.

Click to read the study in NEJM

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ACE inhibitorsangiotensin receptor blocker (ARB)CoronavirusSARS-CoV-2
Previous Post

Use of legal performance enhancing substances increases risk of future anabolic steroid use

Next Post

Psychosocial interventions significantly improve immune system functionality

RelatedReports

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients
StudyGraphics

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

June 30, 2022
Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

June 22, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Next Post

Psychosocial interventions significantly improve immune system functionality

Many new pediatric asthma cases attributable to obesity

2 Minute Medicine Rewind June 15, 2020

#VisualAbstract: Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid19

#VisualAbstract: Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid19

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
  • FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
  • Early initiation of poststernotomy cardiac rehabilitation exercise training is effective and safe
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.